Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04061980
Title Encorafenib and Binimetinib With or Without Nivolumab in Treating Patients With Metastatic Radioiodine Refractory BRAF V600 Mutant Thyroid Cancer
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors OHSU Knight Cancer Institute

thyroid gland cancer


Binimetinib + Encorafenib

Binimetinib + Encorafenib + Nivolumab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST